Results : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
In both WT mice and TLR2/4 KO mice, a significantly higher number of inflammatory cells were found infiltrating around the peri-implant tissues in the ligation group compared with the non-ligation group (Fig. 4a–c). However, the number of inflammatory cells in tissues of the ligation group was not significantly changed when treated with anti-RANKL antibody alone in both WT and TLR2/4 KO mice compared with the ligation group (Fig. 4b, c). MiR-146a treatment additional to anti-RANKL antibody significantly decreased the number of inflammatory cells in WT mice but not in TLR2/4 KO mice when compared with the anti-RANKL antibody alone group. Taken together, anti-RANKL antibody alone did not affect inflammatory cell infiltration in peri-implantitis, and miR-146a showed anti-inflammatory effects only on WT mice but not on TLR2/4-deficient mice.
Gingival TNF-α mRNA showed a significant upregulation in the ligation group compared with the non-ligation group in both WT and TLR2/4 KO mice (Fig. 5a, b). Moreover, TNF-α showed no significant decrease when treated with anti-RANKL antibody alone in both WT and TLR2/4 KO mice compared with the ligation group. However, additional miR-146a treatment significantly decreased TNF-α expression in WT mice but not in TLR2/4 KO mice (Fig. 5a, b), suggesting the consistent results of anti-inflammation effects characterized by quantification of infiltrating inflammation cells (Fig. 4a–c). Meanwhile, gingival RANKL mRNA expression was significantly decreased with anti-RANKL antibody alone in both WT and TLR2/4 KO mice, and additional miR-146a treatment did not show significant difference compared with the anti-RANKL antibody treatment group (Fig. 5c, d). Taken together, anti-RANKL antibody showed the inhibition effects on RANKL expression in both WT and TLR2/4 KOTLR2/4 KO mice, and miR-146a showed anti-inflammation effect through downregulation of TNF-α mRNA only in WT mice.
Serial posts:
- Abstract : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Abstract : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Background : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Background : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Methods : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Methods : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Methods : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [3]
- Results : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Results : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Discussion : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Discussion : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Conclusions : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Availability of data and materials : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Abbreviations : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [3]
- References : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [4]
- Acknowledgements : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Funding : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Author information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [1]
- Author information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling [2]
- Ethics declarations : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Additional information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Supplementary information : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Rights and permissions : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- About this article : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Table 1 Success rate (SR) of osseointegrated implants 4 weeks after implant placement : RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
- Fig. 1. Mouse model of ligature-induced experimental peri-implantitis. (a) Tooth extraction: left maxillary first and second molars extracted at 4 weeks old and the tooth extraction socket healed well with smooth gingiva surface after 6 weeks post-extraction. Implant placement: implant was put in alveolar bone without flap elevation. Ligature placement: at 4 weeks post-implant, 7-0 ligatures were applied under the fixture head. Gingival injection: injections for animals were administered three times on days 3, 6, and 9 during 14 days ligation period. Sample collection: 14 days post-ligation, the gingival tissues and the skulls were collected. (b) Images depicting processing steps of the experimental design (scale bar, 500 μm) : RANKL blockade alleviates peri-implant
- Fig. 2. Anti-RANKL and anti-RANKL+miR-146a treatments decreased ligature-induced bone resorption with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. Buccal side images of the defleshed skulls were taken of the control (non-ligation) group, ligation (non-treatment) group, ligation with anti-RANKL antibody (ligation+AR) treatment group, and ligation with anti-RANKL antibody + miR-146a (ligation+A+MiR) treatment group in WT mice and TLR2/4 KO mice (a) (scale bar, 500 μm). The bone resorption area based on these images was measured and analyzed for WT mice (b) and TLR2/4 KO mice (c) (mean ± SD, n = 6, *p < 0.05, **p < 0.01, SEM, standard error of difference between two means). Three dimension (3D) images from μCT were collected and analyzed for WT mice (d) and TLR4 KO mice (e) (mean ± SD, n = 6, *p < 0.05, **p < 0.01) : RANKL blockade alleviates peri-implant
- Fig. 3. Anti-RANKL and anti-RANKL+miR-146a treatments decreased TRAP-positive cell quantities with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. TRAP-positive cells (red color) with 3 or more nuclei were considered osteoclasts and were shown in the control group, ligation group, ligation with anti-RANKL antibody treatment group, and ligation with anti-RANKL antibody + miR-146a treatment group in WT mice and TLR2/4 KO mice (a) (Im, implant; Av, alveolar bone; scale bar, 100 μm). The quantities of TRAP-positive cells were analyzed in each group of WT mice (b) and TLR2/4 KO mice (c) (mean ± SD, n = 6, **p < 0.01) : RANKL blockade alleviates peri-implant
- Fig. 4. Anti-RANKL and anti-RANKL+miR-146a treatments decreased the inflammatory cell infiltration of the implant gingival tissues with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. HE staining of the gingival tissue around implants were performed in the control group, ligation group, ligation with anti-RANKL antibody treatment group, and ligation with anti-RANKL antibody + miR-146a treatment group in WT mice and TLR2/4 KO mice (a) (scale bar, 100 μm). Inflammatory cell numbers were measured and analyzed in each group of WT mice (b) and TLR2/4 KO mice (c) (mean ± SD, n = 6, **p < 0.01) : RANKL blockade alleviates peri-implant
- Fig. 5. Anti-RANKL and anti-RANKL+miR-146a treatments decreased gingival mRNA expression of TNF-α and RANKL with different patterns in experimental peri-implantitis of WT and TLR2/4 KO mice. Gingival tissues around ligatured implants and non-ligation implants were excised and processed for RT-qPCR analysis to determine mRNA level of TNF-α of WT mice (a) and TLR2/4 KO mice (b) (mean ± SD, n = 6, *p < 0.05, **p < 0.01) and mRNA level of RANKL of WT mice (c) and TLR2/4 KO mice (d) (mean ± SD, n = 6, *p < 0.05, **p < 0.01). : RANKL blockade alleviates peri-implant